Korro BioKRRO +3.57%6 PS Ratio is 33.46 as of Jul. 01, 2026, which is 14% above its 10-year median of 29.40. GuruFocus rates KRRO with a GF Score™ of 6/100. The stock has 5 warning signs investors should review. Among 934 Biotechnology companies, Korro Bio ranks worse than 73.34% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Korro Bio's share price is $13.65.
Korro Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.41. Hence, Korro Bio's PS Ratio for today is 33.46.
The historical rank and industry rank for Korro Bio's PS Ratio or its related term are showing as below:
KRRO'
s PS Ratio Range Over the Past 10 Years
Min: 7.26 Med: 29.4 Max: 177.02
Current: 33.45
During the past 5 years, Korro Bio's highest PS Ratio was 177.02. The lowest was 7.26. And the median was 29.40.
KRRO's PS Ratio is ranked worse than 73.34% of 934
companies
in the Biotechnology industry
Industry Median: 9.515
vs KRRO: 33.45
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Korro Bio PS Ratio Related Terms
Korro Bio PS Ratio Historical Data
* Premium members only.
The historical data trend for Korro Bio's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Korro Bio's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korro Bio PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Korro Bio's PS Ratio distribution charts can be found below:
* The bar in red indicates where Korro Bio's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Korro Bio's Share Price of today is $13.65. Korro Bio's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.41.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Korro Bio (KRRO) has a PS Ratio of 33.46 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Korro Bio and its competitors. This is 14% above median its historical median of 29.40. Over the past decade, Korro Bio's PS Ratio has ranged from 7.26 to 177.02. According to the industry distribution chart, Korro Bio ranks #685 out of 934 companies in the Biotechnology industry, placing it in the top 73.3%.
Is Korro Bio's PS Ratio too high?
Korro Bio's current PS Ratio of 33.46 is 14% above median its 10-year median of 29.40. Over the past 10 years, this metric has ranged from a low of 7.26 to a high of 177.02. The Biotechnology industry median PS Ratio is 9.52. Korro Bio's value of 33.46 is 251.7% above this industry median. Based on the distribution chart, Korro Bio ranks #685 out of 934 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Korro Bio has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Korro Bio's PS Ratio compare to LENZ and ANTX?
According to the Biotechnology industry distribution chart, Korro Bio ranks #685 out of 934 companies for PS Ratio. This places Korro Bio in the lower half of its industry. The industry median PS Ratio is 9.52. Korro Bio's value of 33.46 is 251.7% above this benchmark. Historically, Korro Bio's own PS Ratio has ranged from 7.26 to 177.02 over the past decade. While the company's 10-year median is 29.40 vs. the industry median of 9.52, Korro Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Korro Bio's current PS Ratio of 33.46 is 251.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Korro Bio and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Korro Bio's current PS Ratio is 33.46, which is 14% above median its own 10-year median of 29.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korro Bio stock overvalued right now?
Korro Bio (KRRO) has a current PS Ratio of 33.46. The current PS Ratio is 33.46, which is 14% above median its 10-year median of 29.40 and 251.7% above the Biotechnology industry median of 9.52. Korro Bio's overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Korro Bio (KRRO), the current PS Ratio is 33.46 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
6GF Score
Get the complete analysis for KRRO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KRRO has been successfully added to your 
